Australia markets open in 5 hours 51 minutes

    +102.00 (+1.34%)

    +0.0052 (+0.74%)
  • ASX 200

    +91.50 (+1.25%)
  • OIL

    +0.62 (+0.86%)
  • GOLD

    -1.60 (-0.09%)

    -1,522.16 (-2.11%)
  • CMC Crypto 200

    +12.23 (+0.94%)

Indonesia in talks to buy Merck's COVID-19 antiviral pill - minister

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

JAKARTA, Oct 25 (Reuters) - Indonesia is "finalising" a deal with Merck & Co to procure its experimental antiviral pills, named molnupiravir, to treat COVID-19 ailments, its health minister said on Monday.

Results from a large clinical trial this month showed that the pill, made with Ridgeback Biotherapeutics, cut hospitalisations and deaths by 50%. Merck asked for an emergency use clearance from the United States earlier this month.

Health Minister Budi Gunadi Sadikin told a news conference that the deal is being finalised so that the first shipment of molnupiravir may come at the end of the year after a visit to the company in the U.S.

"So that we have enough stock to withstand a potential next wave," he said, adding that Indonesia and Merck are in talks to build a production plant in Indonesia to produce raw material.

Budi did not say how many pills are being procured. Merck did not immediately respond to a request for comment.

Merck has signed supply deals for the drug with Indonesia's neighbours Malaysia and Singapore, as well as Britain.

Indonesia was Asia's COVID-19 epicentre in July, largely fuelled by the virulent Delta variant, although cases and deaths have largely plummeted recently.

The government said on Monday it is anticipating a potential infection spike brought by the upcoming Christmas holidays. (Reporting by Stanley Widianto; Editing by Christian Schmollinger)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting